Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S. G. Highway, Chharodi, Ahmedabad, 382 481, India.
Mol Divers. 2017 Aug;21(3):741-759. doi: 10.1007/s11030-017-9752-9. Epub 2017 Jun 2.
Cancer is a second major disease after metabolic disorders where the number of cases of death is increasing gradually. Mammalian target of rapamycin (mTOR) is one of the most important targets for treatment of cancer, specifically for breast and lung cancer. In the present research work, Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) studies were performed on 50 compounds reported as mTOR inhibitors. Three different alignment methods were used, and among them, distill method was found to be the best method. In CoMFA, leave-one-out cross-validated coefficients [Formula: see text], conventional coefficient [Formula: see text], and predicted correlation coefficient [Formula: see text] values were found to be 0.664, 0.992, and 0.652, respectively. CoMSIA study was performed in 25 different combinations of features, such as steric, electrostatic, hydrogen bond donor, hydrogen bond acceptor, and hydrophobic. From this, a combination of steric, electrostatic, hydrophobic (SEH), and a combination of steric, electrostatic, hydrophobic, donor, and acceptor (SEHDA) were found as best combinations. In CoMSIA (SEHDA), [Formula: see text], [Formula: see text] and [Formula: see text] were found to be 0.646, 0.977, and 0.682, respectively, while in the case of CoMSIA (SEH), the values were 0.739, 0.976, and 0.779, respectively. Contour maps were generated and validated by molecular dynamics simulation-assisted molecular docking study. Highest active compound 19, moderate active compound 15, and lowest active compound 42 were docked on mTOR protein to validate the results of our molecular docking study. The result of the molecular docking study of highest active compound 19 is in line with the outcomes generated by contour maps. Based on the features obtained through this study, six novel mTOR inhibitors were designed and docked. This study could be useful for designing novel molecules with increased anticancer activity.
癌症是继代谢紊乱之后的第二大疾病,其死亡病例数量正逐渐增加。哺乳动物雷帕霉素靶蛋白(mTOR)是治疗癌症的最重要靶点之一,尤其是乳腺癌和肺癌。在本研究工作中,对 50 种报道的 mTOR 抑制剂进行了比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)研究。使用了三种不同的对齐方法,其中蒸馏法被发现是最佳方法。在 CoMFA 中,发现留一法交叉验证系数 [Formula: see text]、传统系数 [Formula: see text] 和预测相关系数 [Formula: see text] 值分别为 0.664、0.992 和 0.652。进行了 CoMSIA 研究,使用了 25 种不同的特征组合,如立体、静电、氢键供体、氢键受体和疏水。从中,发现立体、静电、疏水(SEH)和立体、静电、疏水、供体和受体(SEHDA)的组合是最佳组合。在 CoMSIA(SEHDA)中,[Formula: see text]、[Formula: see text] 和 [Formula: see text] 分别为 0.646、0.977 和 0.682,而在 CoMSIA(SEH)的情况下,这些值分别为 0.739、0.976 和 0.779。生成并通过分子动力学模拟辅助分子对接研究验证了等高线图。将最高活性化合物 19、中等活性化合物 15 和最低活性化合物 42 对接在 mTOR 蛋白上,以验证我们的分子对接研究结果。最高活性化合物 19 的分子对接研究结果与等高线图的结果一致。基于通过这项研究获得的特征,设计并对接了六个新的 mTOR 抑制剂。这项研究可能有助于设计具有更高抗癌活性的新型分子。